Aberrant JMJD6 catalysis is associated with the upregulation of androgen receptor splice variant 7 (AR‐V7), which confers resistance towards antiandrogens used for prostate cancer treatment; JMJD6 is thus a promising cancer target. This evidence concerns the gene JMJD6 and prostate carcinoma.